Enavogliflozin, an SGLT2 Inhibitor, Improves Nonalcoholic Steatohepatitis Induced by High-Fat, High-Cholesterol Diet
Diabetes & Metabolism Journal · 2026
DOI: 10.4093/dmj.2024.0259 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes & Metabolism Journal, 2026. Verfasst von Phuc Thi Minh Pham und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Kangwon National University School of Medicine, Chuncheon, Korea. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Sodium-Glucose Transporter 2 Inhibitors, Diet, High-Fat, Benzhydryl Compounds. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Daewoong Pharmaceuticals.
Abstract (Originalsprache)
Background
Nonalcoholic fatty liver disease, a progressive condition caused by the accumulation of fat in the liver, begins with simple steatosis and can potentially progress to metabolic dysfunction-associated steatohepatitis (MASH) in the presence of inflammation and fibrosis, ultimately leading to cirrhosis or hepatocellular carcinoma. Increasing evidence indicates that sodiumglucose cotransporter 2 (SGLT2) inhibitors effectively alleviate MASH in mouse models. However, there is a lack of research on the effects of enavogliflozin on liver disease. In the present study, we investigated the effects of SGLT2 inhibitors on MASH induced by a high-fat, high-cholesterol (HFHC) diet in mice.
Methods
Male C57BL/6 mice were fed a normal chow diet, HFHC diet, or HFHC diet with enavogliflozin for 12 weeks. LX-2 and HepG2 cells were treated with enavogliflozin in the presence of various pathological stimuli.
Results
The HFHC diet induced excessive hepatic lipid accumulation, inflammation, and severe fibrosis. Administration of enavogliflozin not only ameliorated hepatic steatosis and fibrotic conditions but also suppressed the production of inflammatory cytokines. Positive outcomes were also observed in in vitro experiments, where enavogliflozin demonstrated the ability to impede the activation of hepatic stellate cells and alleviate lipid accumulation in hepatocytes. The potential pathway through which enavogliflozin attenuated liver fibrosis development may be associated with the transforming growth factor β1/Smad signaling pathway.
Conclusion
Our results suggest that enavogliflozin is effective in a mouse model of MASH by attenuating hepatic steatosis, suppressing inflammation, and improving liver fibrosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Kangwon National University School of Medicine, Chuncheon, Korea.
- Department of Pediatrics, Kangwon National University School of Medicine, Chuncheon, Korea.
Förderung
- Daewoong Pharmaceuticals
Zitieren
APA
Pham, P. T. M., Nguyen, G., Park, S. Y., Lai, T. L., Choi, D. H., Hong, J., Kang, S. M., & Cho, E. H. (2026). Enavogliflozin, an SGLT2 Inhibitor, Improves Nonalcoholic Steatohepatitis Induced by High-Fat, High-Cholesterol Diet. Diabetes & Metabolism Journal. https://doi.org/10.4093/dmj.2024.0259
Vancouver
Pham PTM, Nguyen G, Park SY, Lai TL, Choi DH, Hong J, et al. Enavogliflozin, an SGLT2 Inhibitor, Improves Nonalcoholic Steatohepatitis Induced by High-Fat, High-Cholesterol Diet. Diabetes & Metabolism Journal. 2026. doi:10.4093/dmj.2024.0259
BibTeX
@article{Pham2026,
author = {Pham, Phuc Thi Minh and Nguyen, Giang and Park, So Young and Lai, Thuy Linh and Choi, Dae-Hee and Hong, Jeana and Kang, Seon Mee and Cho, Eun-Hee},
title = {Enavogliflozin, an SGLT2 Inhibitor, Improves Nonalcoholic Steatohepatitis Induced by High-Fat, High-Cholesterol Diet},
journal = {Diabetes & Metabolism Journal},
year = {2026},
doi = {10.4093/dmj.2024.0259}
}
EUVIMED